DUBLIN, December 08, 2021–(BUSINESS WIRE)–The "Diabetes Drug Intelligence Center 2012-2023" report has been added to ResearchAndMarkets.com's offering.
This global intelligence database on diabetes drugs covers data for 25 major countries. It covers 13 years of comparable data, with a five-year forecast, including value, volume sales, price, and price per capita expenditure.
The intelligence center enhances your understanding of the diabetes drugs industry, along with the economic factors impacting the diabetes drugs usage, such as diabetic population levels for Type 1 and Type 2 diabetes, and obesity, which will provide you with actionable business insights.
Companies Mentioned
Astellas
AstraZeneca
Boehringer Ingelheim
Bristol Myers Squibb
Eli Lilly
Janssen Pharmaceuticals
Merck and Co.
Novartis
Novo Nordisk
Pfizer
Sanofi
Takeda
Market Scope
The diabetes drugs market data, volume, and value analytics with growth trend (2012-2023)
Branded and generic drugs sales data for 2012-2023
Additional information includes diabetic population levels, diabetes prevalence, Type-1 diabetic population levels, Type-2 diabetic population levels, and per capita expenditure.
It provides exhaustive coverage (countries covered account for more than 80% of the overall spending on diabetes), covering and tracking of over 18,000 data points of the diabetes drugs industry that covers various category, segments, active pharmaceutical ingredients (API), and brands.
Categories:
Insulin
Basal Insulin or Long-acting Insulin
Bolus Insulin or Fast-acting Insulin
Pre-mixed Insulin or Combination Insulin
Traditional Human Insulin
Traditional Human Insulin Biosimilars
Insulin Glargine Biosimilars
Non-insulin Injectable
GLP-1 Agonist Market
Amylin Analogue
Oral Anti-diabetics Drugs
Dopamine -D2 Receptor Agonist
Meglitinide
Alpha-Glucosidase Inhibitors
SGLT2 Inhibitors
Biguanides
Sulfonylureas
DPP-4 Inhibitors
Combination Drugs
Insulin Combinations
Oral Combinations
Market Overview
The global diabetes drugs market is expected to reach USD 94 billion by 2023 at a CAGR of 5.65%, during the forecast period. The insulin segment of the market studied holds the highest market share and it is mostly consolidated by leading companies, like Sanofi, Novo Nordisk, and Eli Lilly, who account for more than 80% of the insulin supplyglobally. Each of these companies has established their brands in the market. However, due to high competitions in the local markets, consumer penetration for their products is being worked on continuously.
Global Rise in Diabetic Population:
There has been a tremendous increase in the diabetic population levels globally, over the last decade. Several reports and surveys documented a drastic increase in the diabetic population levels, based on the changing lifestyle and habits.
Extensive urbanization in various parts of the world is considered to be the primary cause of obesity, health deterioration, physical inactivity, etc. Owing to these factors, the prevalence of Type-2 diabetes mellitus (T2DM) has increased significantly.
It is estimated that out of the total 415 million people suffering from diabetes worldwide, 46% of this demographic is those with undiagnosed diabetes.
Oral insulin drugs will boost the diabetes drugs market
Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of Type-1 and Type-2 diabetes mellitus. The fast-acting oral insulin may improve post-prandial glucose control with reduced side effects and greater adherence, thus, holding the promise to transform Type-1 diabetes management.
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, focused on the development of oral drug delivery systems, is working to bring the first oral insulin product to market, thus, providing a more convenient, effective, and safer method for delivering insulin therapy.
Reasons to Purchase this Dashboard
More Granular: Covers more categories, segments, and information on brands at country- and global levels than the other market intelligence providers
Provides an outlook of the market with the recent market data and historical data and market forecast
Ease of Comparability: Our analytics is based on standardized definition across the world to facilitate better comparability of market data
View the market in different ways among categories and geographies, in order to understand where the actual opportunity lies
Market segmentation including quantitative research incorporating the impact of economic and non-economic aspects
Regional- and country- level data integrating the demand and supply forces that are influencing the growth of the market
Market value (in USD million) and volume (in tablet or ml million) data for each segment and sub-segment
Understanding of the market, considering the value and volume changes, and intra-category competition
Dedicated analyst support for research queries and training
Continuous amendment of the yearly database with significant changes updated based on scenarios
Key Topics Covered:
1. Introduction
2. Research Approach and Methodology
3. Market Segmentation
4. Market Indicators
5. Company Share Analysis
For more information about this report visit https://www.researchandmarkets.com/r/gum6yw
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005486/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Yahoo Finance's Anjalee Khemlani joins the Live show to report on Pfizer announcing its vaccine boosters have proved effective against the COVID-19 Omicron variant.
(Bloomberg) — Amid the rusted remnants of Venezuela’s once-mighty oil industry, a motley crew of obscure drillers has achieved a feat few thought possible: It’s more than doubled the country’s crude production in the space of a year.Most Read from BloombergThe World’s Relentless Demand for Chips Turns Deadly in MalaysiaSand and Soldiers Mix as Troops Move In to Protect Cancun TouristsEven in the Metaverse, Not All Identities Are Created EqualThe $300 Billion Plan to Bring Green Power to China’s
The newly minted steel company has trounced the market and its peers since the bear market bottom. Is it worth buying?
Shares of Novavax (NASDAQ: NVAX) were soaring 24.1% higher as of 12:35 p.m. ET on Tuesday. European Medicines Agency head Emma Cooke told European Union health ministers on Tuesday that Novavax's COVID-19 vaccine could be authorized in the "near future." Also, a study led by the University of Oxford found that a second dose of Novavax's vaccine following an initial dose of AstraZeneca's (NASDAQ: AZN) vaccine was significantly more effective than two doses of the AstraZeneca vaccine.
It has been a volatile couple of weeks for Covid-19 vaccine makers, as investors battle to assess the impact of the Omicron variant while waiting for answers to crucial questions.
Crowdstrike CEO George Kurtz joins Yahoo Finance Live to discuss the surge in ransomware attacks throughout the pandemic and how fellow cybersecurity firms are losing trust in Microsoft.
The benchmark SPDR S&P Biotech ETF (NYSEMKT: XBI) recently started to recover, but it's still down more than 33% from a peak it reached this February. Editas Medicine (NASDAQ: EDIT) shares are down a whopping 54% over the past three months. It's been falling harder than most biotech stocks this year thanks to disappointing clinical trial results for its lead candidate, EDIT-101.
The charts of the IT company indicate its shares could be seeing some light at the end of the tunnel.
Vaccine stocks were muted Tuesday after test results indicated omicron might elude some of the protection provided by Pfizer's Covid shot.
These companies produce the only thing that matters.
BioNTech and Pfizer said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant in a laboratory test and said they could deliver an upgraded vaccine in March 2022 if needed. BioNTech and Pifzer are the first manufacturers of a COVID vaccine to issue an official update on the efficacy of their shot against Omicron.
Apple did not immediately respond to a Reuters request for comment. The five-year agreement was made when Cook made visits to China in 2016 to quash a host of regulatory action against the company, the report said, citing interviews and internal Apple documents. Cook lobbied Chinese officials, who believed the company was not contributing enough to the local economy, and signed the agreement with a Chinese government agency, making concessions to Beijing and winning key legal exemptions, the report added.
(Bloomberg) — Former U.S. Secretary of State Rex Tillerson was diagnosed with kidney cancer just months after his infamous 2018 firing via tweet by then-President Donald Trump.Most Read from BloombergThe World’s Relentless Demand for Chips Turns Deadly in MalaysiaSand and Soldiers Mix as Troops Move In to Protect Cancun TouristsEven in the Metaverse, Not All Identities Are Created EqualThe $300 Billion Plan to Bring Green Power to China’s MegacitiesMeet the New Climate Refugee in Town: CoyotesT
As the economy has steadily reopened, Matthew Lynn says one of the unexpected consequences of the pandemic has been a “great retirement” of older workers choosing not to return to work and instead to live comfortably on their savings and investments.
(Bloomberg) — European natural gas prices extended gains as one of the region’s biggest fields curbed output because of a fault. Most Read from BloombergThe World’s Relentless Demand for Chips Turns Deadly in MalaysiaSand and Soldiers Mix as Troops Move In to Protect Cancun TouristsEven in the Metaverse, Not All Identities Are Created EqualThe $300 Billion Plan to Bring Green Power to China’s MegacitiesMeet the New Climate Refugee in Town: CoyotesShipments from Norway are expected to slump by n
Amazon.com Inc's push to recruit big-rig contractors to haul goods across its web of warehouses is colliding with a trucker shortage as the e-commerce company moves what are expected to be record numbers of packages this holiday season. Its project, called Amazon Freight Partners (AFP), enlists independent trucking companies to move goods between Amazon facilities. The companies, or AFPs, all of which are exclusive Amazon contractors, also move packages to and from the company's fleet of 85 owned or leased North American airplanes.
Toyota Motor will build its first battery factory in the U.S. in North Carolina, the company and state officials confirmed Monday, as more automakers seek to take control of the supply chain with in-house battery manufacturing plants. Toyota will invest $1.29 billion in the plant, which will be called Toyota Battery Manufacturing, North Carolina (TBMNC), with production anticipated to commence in 2025.
Ford Motor Co is investing $900 million to upgrade factories in Thailand that build its Ranger pickup truck and Everest SUV, its largest-ever investment in the country. The plan includes a near doubling of the number of robots at its Thai manufacturing plant and at AutoAlliance Thailand, a venture with Mazda Motor Corp, while $400 million of the investment will go towards its supply chain network. It will also add a second shift to the Ford plant which will result in as many as 1,250 new jobs, bringing its workforce in Thailand to more than 9,000.
The last several weeks have been rough for tech investors, as many richly valued growth stocks have seen their share prices fall sharply, in some cases by more than 10% in a single day. That's why investors should consider buying this beaten-down tech stock.
Upstart and SEMrush have fallen about 47% and 28%, respectively, yet both companies have been executing and showed strength in their third-quarter reports. Upstart is bringing optimal credit to a segment of people that might have never received it before. The company partners with banks to determine credit worthiness in what some consider a radical way.
